+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 47 Pages
  • August 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5654053
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Drugs In Development, 2022, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 9 and 1 respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Retinoblastoma - Overview
  • Retinoblastoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Retinoblastoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Retinoblastoma - Companies Involved in Therapeutics Development
  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Ascentage Pharma Group International
  • Canget BioTekpharma LLC
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Cothera Bioscience Pty Ltd
  • Innovation Pharmaceuticals Inc
  • Oxular Ltd
  • PepVax Inc
  • Seneca Therapeutics Inc
  • Spectocular LLC
  • Targeted Therapy Technologies LLC
  • VCN Biosciences SL
  • Retinoblastoma - Drug Profiles
  • APG-115 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • conbercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Drug to Inhibit MDM2 for Retinoblastoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • FL-761 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • FL-7729 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • FL-7N1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Kevetrin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • lorukafusp alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • OXU-003 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • PC-002p - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PVX-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • sulanemadlin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SVV-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • topotecan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • VCN-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Retinoblastoma - Dormant Projects
  • Retinoblastoma - Product Development Milestones
  • Featured News & Press Releases
  • Feb 08, 2022: Synthetic Biologics announces VCN Biosciences' VCN-01 receives orphan drug designation for retinoblastoma from the U.S. FDA
  • Oct 12, 2020: Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for retinoblastoma treatment
  • Jan 24, 2019: SJD Barcelona Children’s Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01
  • Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
  • Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
  • Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
  • Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
  • Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
  • Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Retinoblastoma, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Retinoblastoma - Pipeline by Aileron Therapeutics Inc, 2022
  • Retinoblastoma - Pipeline by APEIRON Biologics AG, 2022
  • Retinoblastoma - Pipeline by Ascentage Pharma Group International, 2022
  • Retinoblastoma - Pipeline by Canget BioTekpharma LLC, 2022
  • Retinoblastoma - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022
  • Retinoblastoma - Pipeline by Cothera Bioscience Pty Ltd, 2022
  • Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, 2022
  • Retinoblastoma - Pipeline by Oxular Ltd, 2022
  • Retinoblastoma - Pipeline by PepVax Inc, 2022
  • Retinoblastoma - Pipeline by Seneca Therapeutics Inc, 2022
  • Retinoblastoma - Pipeline by Spectocular LLC, 2022
  • Retinoblastoma - Pipeline by Targeted Therapy Technologies LLC, 2022
  • Retinoblastoma - Pipeline by VCN Biosciences SL, 2022
  • Retinoblastoma - Dormant Projects, 2022
List of Figures
  • Number of Products under Development for Retinoblastoma, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Ascentage Pharma Group International
  • Canget BioTekpharma LLC
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Cothera Bioscience Pty Ltd
  • Innovation Pharmaceuticals Inc
  • Oxular Ltd
  • PepVax Inc
  • Seneca Therapeutics Inc
  • Spectocular LLC
  • Targeted Therapy Technologies LLC
  • VCN Biosciences SL